Repr
gramming
gramming
immunity
gramming
At ReWire, we unite expertise in genomics, immunology, and gene therapy to tackle the root cause of autoimmune and inflammatory diseases. Our platform reprograms T cells in vivo with unmatched specificity.
Guided by world-class science from the University of Oxford, we are building curative therapies that go beyond symptom management, restoring the body's own immune regulation.
Fully functional TRANCERs can be minimised to 400bp, making them ideal for size-constrained viral delivery vectors.
Express two functional transcripts from one construct enabling all-in-one gene editing systems.
Works with ML-designed synthetic enhancers or can use AI for enhancer feature improvements.
Proven across mammalian cell lines, organoids, and in vivo in zebrafish and mice.
Patent number: PCT/GB2025/052425, publication 5th June 2026.
ReWire's TRANCER platform reprograms T cells directly in the body bypassing the costly, complex ex vivo manufacturing that limits current Treg therapies.